Going forward, if a vaccinator wants to approve his Kovade 19 vaccine for use in healthy children and healthy adults under the age of 65, they will have to conduct large, randomly -controlled studies. They may need to include tens of thousands of participants, especially with high levels of immunity in the population. These trials can easily cost hundreds of millions of dollars, and it may take several months to complete them. The need for such trials will be difficult if it is not impossible for drug makers to hold them every year and at a time that will be developed over time for seasonal shots to complete the trial, regulate regulatory approval and start the breath virus.
McCary and Prasad did not provide any data analysis or evidence -based argument as to why additional trials would be required to continue climate approval. In fact, there were only eight references in the commentary, including a piece of opinion published in Newsweek and the New York Times article.
“We just don’t know that a healthy 52 -year -old woman who has a common BMI, who has been three times, has become Koide -19 and will benefit from the seventh dose of six previous vaccines,” she discusses in her comment.
Their new framework does not mention what will happen if the more dangerous SARS-COV-2 different conditions emerge. It does not mention the use of vaccine in people who are in close contact with high -risk groups, such as ICU nurses or family members of immunocoms.
Context
Another lasting question from the framework is how easier it would be for people with more risky access to seasonal shots. Macri and Prasad presented a long list of conditions that would put people at risk of severe covid 19 and for this reason they would be eligible for seasonal boosters. The list includes: obesity; Asthma, lung diseases. Hiv; Diabetes; Pregnancy; Pregnancy diabetes; Heart conditions; The use of corticosteroids; Dementia; Physical inactivity; Mental health conditions, including sadness. And smoking, current or ex. FDA leaders estimates that between 100 million and 200 million Americans will fit into the category of higher risk. It is unclear what such a large group of Americans will need to do every year to establish eligibility.